In context of the ongoing pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the renin–angiotensin–aldosterone system (RAAS) has gained increasing attention due to their link to inflammatory and anti-inflammatory pathways and since concerns were raised regarding a potential influence of angiotensin-converting-enzyme (ACE)-inhibitors (ACE-I) and angiotensin-receptor blockers (ARB) on the susceptibility to infection with SARS-CoV-2 and on the prognosis of corona virus disease 2019 (COVID-19) [2,3,4]. Here, ACE is linked to infection.